Historical Valuation
Armata Pharmaceuticals Inc (ARMP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 45.06 is considered Overvalued compared with the five-year average of -2.97. The fair price of Armata Pharmaceuticals Inc (ARMP) is between 2.01 to 5.08 according to relative valuation methord. Compared to the current price of 7.89 USD , Armata Pharmaceuticals Inc is Overvalued By 55.2%.
Relative Value
Fair Zone
2.01-5.08
Current Price：7.89
55.2%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Armata Pharmaceuticals Inc (ARMP) has a current Price-to-Book (P/B) ratio of -2.49. Compared to its 3-year average P/B ratio of -1.06 , the current P/B ratio is approximately 133.70% higher. Relative to its 5-year average P/B ratio of 0.80, the current P/B ratio is about -412.07% higher. Armata Pharmaceuticals Inc (ARMP) has a Forward Free Cash Flow (FCF) yield of approximately -11.48%. Compared to its 3-year average FCF yield of -52.85%, the current FCF yield is approximately -78.27% lower. Relative to its 5-year average FCF yield of -40.49% , the current FCF yield is about -71.64% lower.
P/B
Median3y
-1.06
Median5y
0.80
FCF Yield
Median3y
-52.85
Median5y
-40.49
Competitors Valuation Multiple
AI Analysis for ARMP
The average P/S ratio for ARMP competitors is 8.64, providing a benchmark for relative valuation. Armata Pharmaceuticals Inc Corp (ARMP.A) exhibits a P/S ratio of 45.06, which is 421.64% above the industry average. Given its robust revenue growth of -61.02%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for ARMP
1Y
3Y
5Y
Market capitalization of ARMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ARMP in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is ARMP currently overvalued or undervalued?
Armata Pharmaceuticals Inc (ARMP) is now in the Overvalued zone, suggesting that its current forward PS ratio of 45.06 is considered Overvalued compared with the five-year average of -2.97. The fair price of Armata Pharmaceuticals Inc (ARMP) is between 2.01 to 5.08 according to relative valuation methord. Compared to the current price of 7.89 USD , Armata Pharmaceuticals Inc is Overvalued By 55.20% .
What is Armata Pharmaceuticals Inc (ARMP) fair value?
ARMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Armata Pharmaceuticals Inc (ARMP) is between 2.01 to 5.08 according to relative valuation methord.
How does ARMP's valuation metrics compare to the industry average?
The average P/S ratio for ARMP's competitors is 8.64, providing a benchmark for relative valuation. Armata Pharmaceuticals Inc Corp (ARMP) exhibits a P/S ratio of 45.06, which is 421.64% above the industry average. Given its robust revenue growth of -61.02%, this premium appears unsustainable.
What is the current P/B ratio for Armata Pharmaceuticals Inc (ARMP) as of Jan 09 2026?
As of Jan 09 2026, Armata Pharmaceuticals Inc (ARMP) has a P/B ratio of -2.49. This indicates that the market values ARMP at -2.49 times its book value.
What is the current FCF Yield for Armata Pharmaceuticals Inc (ARMP) as of Jan 09 2026?
As of Jan 09 2026, Armata Pharmaceuticals Inc (ARMP) has a FCF Yield of -11.48%. This means that for every dollar of Armata Pharmaceuticals Inc’s market capitalization, the company generates -11.48 cents in free cash flow.
What is the current Forward P/E ratio for Armata Pharmaceuticals Inc (ARMP) as of Jan 09 2026?
As of Jan 09 2026, Armata Pharmaceuticals Inc (ARMP) has a Forward P/E ratio of -4.26. This means the market is willing to pay $-4.26 for every dollar of Armata Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Armata Pharmaceuticals Inc (ARMP) as of Jan 09 2026?
As of Jan 09 2026, Armata Pharmaceuticals Inc (ARMP) has a Forward P/S ratio of 45.06. This means the market is valuing ARMP at $45.06 for every dollar of expected revenue over the next 12 months.